These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 8513428)

  • 21. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [ACE-inhibitors and cardiovascular protection].
    Agabiti-Rosei E; Muiesan ML
    Cardiologia; 1994 Dec; 39(12 Suppl 1):139-47. PubMed ID: 7634257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of ACE inhibition on myocardial ischaemia.
    Ferrari R
    Eur Heart J; 1998 Sep; 19 Suppl J():J30-5. PubMed ID: 9796838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The significance of converting enzyme inhibitor angiotensin I to angiotensin II in treatment of patients with coronary disease].
    Halawa B
    Pol Merkur Lekarski; 1998 Jan; 4(19):32-4. PubMed ID: 9553407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials.
    Yusuf S; Lonn E
    Eur Heart J; 1998 Sep; 19 Suppl J():J36-44. PubMed ID: 9796839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
    Healey JS; Morillo CA; Connolly SJ
    Curr Opin Cardiol; 2005 Jan; 20(1):31-7. PubMed ID: 15596957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE; McKinnie JJ; Greenberg SS; Giles TD
    Prog Cardiovasc Dis; 1999; 41(4):265-300. PubMed ID: 10362349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
    Carson PE
    Am Heart J; 2000 Sep; 140(3):361-6. PubMed ID: 10966531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [ACE inhibitors in the treatment of patients with acute myocardial infarct].
    Borghi C; Ambrosioni E
    Ann Ital Med Int; 1995; 10(3):175-87. PubMed ID: 7577315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Anti-ischemic and infarction-reducing effects of angiotensin-converting enzyme inhibitors].
    Landmark K; Aursnes I
    Tidsskr Nor Laegeforen; 2001 Jun; 121(16):1923-6. PubMed ID: 11488184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].
    Azizi M
    Rev Prat; 2004 Jun; 54(11):1167-74. PubMed ID: 15496022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evolution of myocardial ischemia therapy: calcium antagonists and ACE-inhibitors].
    Ferrari R
    Cardiologia; 1994 Dec; 39(12 Suppl 1):203-6. PubMed ID: 7634268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury: an overview.
    Zughaib ME; Sun JZ; Bolli R
    Basic Res Cardiol; 1993; 88 Suppl 1():155-67. PubMed ID: 8357331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RAS inhibition in hypertension.
    Ibrahim MM
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential role of angiotensin-converting enzyme inhibition in myocardial ischemia and current clinical trials.
    Pepine CJ
    Clin Cardiol; 1997 Nov; 20(11 Suppl 2):II-58-64. PubMed ID: 9422854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The role of ACE-inhibition in the therapy of chronic heart insufficiency].
    Drexler H; Just H
    Wien Med Wochenschr; 1990 Jan; 140(1-2):40-5. PubMed ID: 2137955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac arrhythmias--a new indication for angiotensin-converting enzyme inhibitors?
    Wesseling H; de Graeff PA; van Gilst WH; Kingma JH; de Langen CD
    J Hum Hypertens; 1989 Jun; 3 Suppl 1():89-95. PubMed ID: 2674445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension. Do we need more clinical trials?
    Sambhi MP; Gavras H; Robertson JI; Smith WM
    West J Med; 1993 Mar; 158(3):286-94. PubMed ID: 8460511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [ACE-inhibitors: physiologic premises and pharmacologic profiles].
    Marino A; Schettini G; Florio T; Ventra C
    Clin Ter; 1990 Feb; 132(4):267-76. PubMed ID: 2140314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.